袋鼠

$ROBOTPHOENIX(06871.HK) rose by over ten percentage points, while $LAIFUAL(03952.HK) actually fell slightly. The World Artificial Intelligence Conference is opening next week and, for the first time, has set up an Embodied AI zone. Sentiment for humanoid robots (the main body) has already been ignited, but upstream components like harmonic reducers haven't kept up. Is it that capital is first speculating on the whole machines catalyzed by the conference, leaving component parts aside, or is it that the upstream sector simply can't keep pace with the main body's rhythm? It looks more like the former. $ROBOTPHOENIX(06871.HK) also has the added catalysts of an exclusive agency agreement with South Korea's MiR and the launch of Hongjun 001, giving it more momentum. $LAIFUAL(03952.HK) lacks its own news and is prone to falling behind in this kind of thematic market.

$Regencell Bioscience(RGC.US) has dropped another -14%. It was previously pushed up by a short squeeze, but now it's under pressure from a DOJ investigation, class-action lawsuits, and widening losses. For this kind of purely sentiment-driven small-cap Chinese medicine concept stock that's falling, does it count as an opportunity? I won't touch it myself — the decline of a squeeze stock usually isn't a one-off event. Once the shareholding structure loosens, any rebound won't be able to retain investors.

$Global Mofy AI(GMM.US) surged +147% in a single day, with trading volume expanding to two and a half times its usual level. Scouring through the announcements revealed nothing—it just hit a new all-time low on 7/8. This is a classic case of an oversold micro-cap being ignited by capital, with the next day's news already mentioning a post-market pullback.

$Jiuzi(JZXN.US) +85% at least has a story: the company officially announced its intention to sign a cooperation agreement for an AI intelligent imaging platform, with initial cooperation expected to generate about $1.0M in profit. Note the wording—the agreement hasn't been formally signed yet. A $1M profit expectation corresponds to a near-doubling in market cap elasticity in one day. The leverage in these low-float China concept small-cap stocks lies entirely in sentiment.

Both belong to that category of erratic moves with extremely poor sustainability: no fundamental anchor, driven by small float. The capital chasing in wants speed, not logic.

$Hewlett Packard Enterprise(HPE.US) surged significantly today, continuing the momentum from last quarter's record-breaking earnings report—after incorporating Juniper, its networking business more than doubled year-over-year, cloud and AI revenue also reached $7.7 billion, full-year guidance was raised accordingly, and AI order backlog is nearly $6 billion.

Activist shareholders are still applying pressure from behind, and the market is repricing it: from the server manufacturer of earlier years to a supplier of a complete computing, networking, storage, and private cloud computing stack. The rise at this level is more like fundamentals being realized, not just chasing trends.

$Regencell Bioscience(RGC.US) pulled up again, rising nine points, with trading volume several times higher than usual—this is a small-cap stock focused solely on traditional Chinese medicine for ADHD and autism, and it has actually been in a deep decline throughout the year. This move looks more like short covering plus speculative capital entering, with no new clinical or commercialization news released.

For a short squeeze like this, the hard part to judge is the timing: is the short squeeze just starting, or is it another one-day wonder? It seems more like the latter; a squeeze without fundamental support usually can't last more than a few trading days🤔

$Viking Therap(VKTX.US) rose significantly today, as its weight-loss drug pipeline took another step forward – its second candidate, VK3019, just entered a Phase 1 first-in-human single ascending dose trial, while the Phase 3 trials for its main drug, VK2735 (both oral and injectable), are also progressing.

Whenever there's a new data point in the GLP-1 space, $Viking Therap(VKTX.US) has always shown high volatility. This rally is more about pipeline expectations being realized rather than pure sentiment.

$ROBOTPHOENIX(06871.HK) rose 52%, $LAIFUAL(03952.HK) rose 13%. Two Hong Kong-listed robotics secondary new shares experienced a short squeeze together, while $DOBOT(02432.HK) saw a slight pullback. The direct trigger for this wave was the spillover effect from the broad-based limit-up rally in the A-share robotics concept theme. $LAIFUAL(03952.HK), as a leader in harmonic reducers and benefiting from supply chain expectations due to Unitree's approved IPO, has a more solid catalyst. $ROBOTPHOENIX(06871.HK) is more about a short squeeze in a secondary new share with a small float, while $DOBOT(02432.HK) took a breather after a sharp rise.

The recent strength in the robotics reducer chain is essentially a resonance between the mass production expectations for humanoid robots and the scarcity of chips in secondary new shares. The thematic attribute far outweighs earnings realization. The sustainability of this short squeeze depends on how long the sentiment in the A-share market can hold up.

$Aerovironment(AVAV.US) surged over 10% in this wave. The direct catalyst was securing a $500 million contract from the Department of Defense, on top of the previous quarter's earnings which already exceeded expectations. The visibility of defense orders like drones and ammunition has been increasing over the past two years. The landing of a $500 million contract of this magnitude has made the market willing to reprice the order book. The trading volume also expanded to more than double, indicating it's not purely sentiment-driven. Next, we'll see if the delivery pace of this contract can be sustained into the guidance for the next few quarters.

$Big Tree Cloud(DSY.US) surged +55% in a single day. Scouring all the news and information reveals no substantial catalyst. After the reverse stock split, the float is as thin as paper. It's purely funds inside pulling up against thin air. For this kind of baseless impulse move, the speed of the rise is usually matched by the ferocity of the pullback. If you don't have a position, you really shouldn't try to catch this falling knife. 🙈

$Linkhome(LHAI.US) surged +315% in a single day, with trading volume skyrocketing to over 3,000 times its usual level—completing the acquisition of Mortgage One to secure mortgage licenses in 18 states and tens of millions of dollars in warehouse lines, while also announcing plans to pursue AI infrastructure financing and decentralized GPU computing power.

The acquisition is real, but with the stock price more than tripling, it's clearly a case of emotional pricing that layers the two narratives of "mortgage licenses + AI computing power." For such a small-cap ADR with extremely low float, pullbacks after such a run-up are usually swift, making chasing it a poor risk-reward proposition.

$BTC Digital(BTCT.US) rose +21%. The catalyst is that $7 million private placement deposit (with up to $21 million in potential warrants). The money will be used to build an 8MW AI computing power building—transitioning from pure mining to AI hosting. The story makes sense, but the company's market cap was already small, and financing dilution is an obvious cost.

$Abivax SA(ABVX.US) rose +39%, driven by a Phase 3 data turnaround: oral obefazimod's 44-week maintenance data in ulcerative colitis showed a remission rate just over 50%, compared to only 10.4% for placebo, with no new safety signals—this data came out after the 44% crash on June 2nd due to cancer cases in the high-dose group, essentially serving as remedial evidence.

$Aeva Tech(AEVA.US) rose +12% after signing a 4D LiDAR safety collaboration with Bendix Commercial Vehicle Systems, reigniting the robotaxi narrative. However, the company just completed a $115 million follow-on offering, and the CEO personally cashed out $6.76 million—the collaboration is real, but so are the dilution and insider selling.

Behind these three rebounds are a deposit received, data overturned, and a deal landed, but none can avoid the word 'dilution'—which rebound has better quality to withstand next week's test? I lean towards $Abivax SA(ABVX.US). Data is a hard metric; the other two are more propped up by narratives and capital moves.

$KLA(KLAC.US) +12%, $ACM Research(ACMR.US) +14%, $Maxlinear(MXL.US) +12% — on the same day, three semiconductor equipment analysts collectively raised their price targets: Cantor Fitzgerald raised the target for $KLA(KLAC.US) from 250 to 325, and Bank of America followed suit; Morgan Stanley raised the target for $ACM Research(ACMR.US) from 90 to 130, with Roth Capital simultaneously raising it from 100 to 125; Stifel raised the target for $Maxlinear(MXL.US) from 105 to 110.

An additional driver for $KLA(KLAC.US) is 40.8 million shares of short interest + the company's guidance for "advanced packaging process control revenue of approximately $10 billion by 2026"; $ACM Research(ACMR.US) was added to the Russell 2500/3000 Growth index again on 6/27, leading to passive fund buying that week; $Maxlinear(MXL.US) is a continuation of Q1 revenue growth of +43% YoY and new AI data center products. All three are essentially betting on the second wave of the AI computing power chain of "advanced packaging + high-bandwidth memory + data center connectors." Analysts are recalibrating pricing, making them more worth chasing than just looking at the price.

$NetEase(NTES.US) rose by seven or eight points, with the catalyst being the completion of its dual primary listing on the Hong Kong Stock Exchange on 6/30.

Secondary listings of Chinese concept stocks typically see a mild reaction, but $NetEase(NTES.US) directly surged this time. The market clearly views "inclusion in the Stock Connect + decoupling from compliance risks" as a substantive positive.

However, Alibaba and JD.com did the same thing without such a strong move. Is this truly a window for valuation reassessment, or just a one-day event-driven rally? If chasing now, should we wait for a pullback and the ADR price gap to narrow? 🤔

$Applied Materials(AMAT.US) surged over 13%, $Teradyne(TER.US) surged over 10%. This wave of equipment stocks was directly ignited by Micron's record quarterly report—expectations for HBM/DRAM capital expenditures have been raised again. $Applied Materials(AMAT.US) itself also seized the moment to launch six new systems for DRAM and advanced packaging, essentially confirming the narrative that "AI memory production will continue to expand." Both stocks jumped higher at the open. Logically, this doesn't look like a momentary emotional impulse but more like a repricing based on order visibility. Next, we'll watch the pace at which equipment orders materialize.

$Regencell Bioscience(RGC.US) has dropped another -23%, with no new fundamental news. The market pressure still stems more from the shadow of that securities class action lawsuit and the earlier regulatory investigation.

Can you still trust this kind of stock that has zero revenue, propped up by a TCM (Traditional Chinese Medicine) concept to a sky-high market cap, and is now entangled in lawsuits? My view is that the fundamentals column was always empty to begin with. What's been lost is the emotional premium that was hyped up earlier. It's still far from reasonable valuation, and any rebound is only suitable for trading on sentiment, not as a value investment.😵

$Atlantic(ATLN.US) more than doubled directly. The catalyst was its subsidiary securing a four-year ICT contract worth approximately $52 million from the Dutch Vehicle Administration. The day before, Q1 revenue also increased by +143% year-on-year to $250 million.

Confirmed by both the contract and earnings report, it's not purely news-driven momentum. However, for such a small-cap stock with a +200% move in one day, it's highly likely to give back some of those gains later. If you really want to follow, wait for a pullback and assess the volume and momentum then.

$Nexentis Tech(NXTS.US) surged +156% in a single day, all because its subsidiary got on board with Boltz's AI drug discovery line. The narrative is off the charts 🙈

But this company is still burning cash this quarter, with a net loss of over six million USD, and it has a small float. Is this kind of pulse, ignited purely by a single piece of partnership news, the start of a new main trend, or just another emotional rollercoaster? If you don't have a position, it's really not advisable to chase at these levels. If you do have a position, figure out your take-profit point first.

$Wolfspeed(WOLF.US) has risen nearly 20%. The MOU for GE Aviation's 10kV silicon carbide MOSFET is a verifiable firm order. Coupled with the fifth-generation 200mm silicon carbide platform directly addressing the power demands of AI data centers, silicon carbide's shift from automotive-grade to computing power supply has, for the first time, gained endorsement from a major client. The shadow of the previous bankruptcy restructuring has weighed heavily for a long time. This kind of fundamental catalyst is more reliable than a simple sentiment rebound, but valuation is still recovering. To chase it, one must recognize this is order fulfillment, not a news-driven spike.

$Cuprina(CUPR.US) surged +65%, $Park Ha Biological Tech(BYAH.US) also followed with a +40% pump, and $ROBOTPHOENIX(06871.HK) jumped over ten points — three completely unrelated small-cap stocks in medical devices, skincare, and robotics, all pumped to this extent on the same day. It's basically a pulse driven by news flow combined with poor liquidity. For this kind of single-day doubling-level anomaly, is it worth chasing? I personally don't touch them — the float is too small, the volatility is too high. People entering are essentially gambling on whether there will be follow-on funds to take the next baton, not on the company itself. When the pullback comes, it can just as easily wipe out half in a day. Do you guys get itchy fingers when you see these? 😳

$CCH(CCHH.US) surged +50% today, with a volume ratio reaching 74 times.

This company, which operates a chicken hotpot chain in Malaysia and recently listed on Nasdaq, is a small-cap secondary new stock with no new announcements. It was even pumped pre-market the day before, following the same pattern as the recent surge in a batch of ultra-micro caps—small float, no news, purely driven by speculative capital.

The fundamentals of a restaurant chain cannot support such single-day volatility. Once the hype subsides, it's highly likely to fall back down just as quickly as it rose.

$Autozi Internet Tech Global(AZI.US) has risen another 27%, with no new announcements for two consecutive days. The float is only a little over 1.7 million shares, and during the previous session, it even touched +400%. The trouble with this kind of stock isn't how much it rises, but that you have no idea who the other side of the trade is.

The end of a low-float squeeze is usually much faster than the beginning. The likelihood of catching the falling knife now is extremely high: it's always retail investors who get stuck holding the bag at the end of a squeeze. For a stock with no news support, once the volume dries up, it comes straight down.

$Veeco Instruments(VECO.US) surged significantly today, with trading volume more than three times the usual level.

The catalyst is clear: the NSA500 nanosecond annealing system received an additional order from a major advanced logic customer—the evaluation unit was accepted and converted into an official purchase, while a third evaluation unit has already been shipped to another logic customer. There is an expectation that the annealing step in advanced processes could replace laser annealing. The transition of orders from evaluation to mass production is a crucial leap in the company's story.

On the other hand, Barclays raised its target price from $30 to $55 but only gave it a Neutral rating, while the CEO and two directors sold shares at high levels. The orders are real, and the cash-out is real, but this combination looks more like a phased realization of gains rather than the start of a new cycle.

Ambarella has dropped another five or six points, and this round of correction doesn't quite match up with the fundamentals — last quarter's revenue was up 20% year-over-year, and EPS also exceeded expectations, but the stock price has been trending downward ever since the earnings report.

What's really weighing it down is the ITC reaffirming GoPro's patent claims against Insta360, and the Insta360 sports camera supply chain uses Ambarella's chips. The market is worried about downstream shipments being affected. The growth logic of edge AI vision hasn't been broken, but the valuation has already priced in high expectations, lacking an order that can reignite the imagination.

MagnaChip fell 11%. It had a run-up earlier based on the narrative of power MOSFETs in AI server power supplies, but today it got knocked back down a lot by repricing.

Power semiconductors are indeed an easily overlooked part of the AI computing chain, but MagnaChip is small in scale and has high customer concentration, so there's never been a consensus on its valuation.

During the pullback, should we build a small position as a flexible bet, or wait for it to squeeze out all expectations first? I lean towards the latter. For a small-cap stock propped up by a single theme, pullbacks often happen more than once.

Both Innodata and Innovent Biologics rose by around +11%, and Shopify also rose by about eight percentage points: Innodata secured a new Big Tech contract worth $51 million, and its pivot to AI data infrastructure is supported by its second-largest client in quantitative terms; Shopify is following the recovery narrative of the SaaS sector and AI recommendations, with no specific catalyst; Innovent Biologics is rebounding with the overall sentiment of the Hong Kong stock innovative drug sector this week.

The nature of the three driving forces is different: Innodata's story relies on order fulfillment, Shopify leans towards valuation repair, and Innovent Biologics is more like a sector sentiment rebound. To distinguish which can continue, the focus should be on Innodata's Q2 customer concentration disclosure and Innovent's clinical progress.